| Current Studies as of April 2024 Solid Tumor Cancers | |||
|---|---|---|---|
| BREAST | |||
| AstraZeneca (CAMBRIA-1) | |||
| Status: | ACTIVE, RECRUITING | ||
| Title: | A Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence | ||
| Purpose: | To evaluate the safety and efficacy of Camizestrant compared to standard endocrine therapy | ||
| Target Population: | Persons 18 years+ with ER+/HER2- early stage breast cancer with an intermediate or high risk of recurrence that have been treated with surgery (with or without radiation) followed by 2 to 5 years of standard endocrine therapy with no disease recurrence. | ||
| Type of Treatment: | Oral Medication | ||
| Link: | https://clinicaltrials.gov/study/NCT05774951 | ||
| BREAST | |||
| AstraZeneca (DESTINY-11) | |||
| Status: | ACTIVE, Not recruiting | ||
| Title: | A Phase 3 Open-Label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-Dxd) Monotherapy or T- DXd followed by THP compared to ddAC-THP in Participants with High-risk HER2+ Early-Stage Breast Cancer | ||
| Purpose: | To evaluate the safety and efficacy of Trastuzumab Deruxtecan (T-Dxd) alone, or T-DXd followed by paclitaxel, trastuzumab and pertuzumab (THP) compared to a standard of care regimen of doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab and pertuzumab (ddAC- THP). | ||
| Target Population: | Persons 18 years+ with untreated, early-stage HER2-positive breast cancer that is locally advanced or inflammatory | ||
| Type of Treatment: | Intravenous Infusion | ||
| Link: | https://clinicaltrials.gov/study/NCT05113251 | ||
| BREAST | |||
| Genentech-Roche (APHINITY) | |||
| Status: | ACTIVE, NOT RECRUITING | ||
| Title: | A Randomized, Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy + Trastuzumab vs Chemotherapy + Trastuzumab + Pertuzumab as Adjuvant Therapy in Patients with Operable HER2+ Primary Breast Cancer | ||
| Purpose: | To evaluate the safety and efficacy of Pertuzumab versus placebo in addition to chemotherapy and trastuzumab in patients with operable HER2+ breast cancer | ||
| Target Population: | Persons 18 years+ with non-metastatic operable HER2+ breast cancer | ||
| Type of Treatment: | Intravenous Infusion | ||
| Link: | https://www.clinicaltrials.gov/study/NCT01358877 | ||
| LUNG - NSCLC | |||
| Abbvie (M18-868) | |||
| Status: | ACTIVE, RECRUITING | ||
| Title: | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non- Small Cell Lung Cancer (NSCLC) | ||
| Purpose: | To compare Telisotuzumab Vedotin to standard of care docetaxel in previously treated patients with EGFR wildtype, locally advanced or metastatic c-Met overexpressing Non-Small Cell Lung Cancer (NSCLC). | ||
| Target Population: | Persons 18 years+ with EGRF wildtype NSCLC (non-squamous) who have progressed on at least one line of prior therapy. | ||
| Type of Treatment: | Intravenous Infusion | ||
| Link: | https://clinicaltrials.gov/study/NCT04928846 | ||
| OVARIAN | |||
| Tesaro/GSK (3000-03-005) | |||
| Status: | ACTIVE, NOT RECRUITING | ||
| Title: | A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer | ||
| Purpose: | To compare platinum-based therapy with TSR-042 and Niraparib with standard of care platinum- based therapy in patients with previously untreated stage III or IV nonmucinous epithelial ovarian cancer | ||
| Target Population: | Persons 18 years+ with previously untreated stage III or IV high-grade, nonmucinous epithelial ovarian cancer | ||
| Type of Treatment: | Intravenous Infusion | ||
| Link: | https://clinicaltrials.gov/study/NCT03602859 | ||
| Leukemia and Lymphoma | |||
| CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | |||
| Janssen (TAILOR) | |||
| Status: | ACTIVE, RECRUITING | ||
| Title: | Phase II Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (Ibrutinib monotherapy or Ibrutinib + Venetoclax) | ||
| Purpose: | To evaluate the safety and efficacy of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which the dose of ibrutinib is either reduced or modified. | ||
| Target Population: | Patients 18 years or older with previously untreated chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) | ||
| Type of Treatment: | Oral medication | ||
| Link: | https://clinicaltrials.gov/study/NCT05963074 | ||
| CHRONIC MYELOGENOUS LEUKEMIA (CML) | |||
| Novartis (ASC2ESCALATE) | |||
| Status: | ACTIVE, RECRUITING | ||
| Title: | A Phase II multicenter, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase – Chronic Myelogenous Leukemia (CML) | ||
| Purpose: | To determine the safety and efficacy of Asciminib, as well as dose tolerability in patients with CML. | ||
| Target Population: | 2nd Line Cohort: Persons 18 years + with Chronic Phase CML without T315I mutation who had 1 prior ATP-binding site TKI discontinued due to treatment failure, warning or intolerance. 1st Line Cohort: Newly diagnosed CML-CP patients without T315I mutation who may have had up to 4 weeks of prior TKI therapy. Patients will be tested at screening for T315I mutation and excluded if the mutation is found. | ||
| Type of Treatment: | Oral Medication | ||
| Link: | https://clinicaltrials.gov/study/NCT05384587 | ||
| NON-HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA | |||
| Regeneron (Olympia-2) | |||
| Status: | ACTIVE, RECRUITING | ||
| Title: | A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20x Anti-CD3 Bispecific Antibody, Combined With Chemotherapy Versus Rituximab Combined With Chemotherapy in Previously Untreated Participants With Follicular Lymphoma | ||
| Purpose: | To determine the efficacy and safety, as well as tolerability and dose of Odronextamab (REGN1979) in combination with chemotherapy compared to a standard of care regimen of chemotherapy in patients with untreated CD20 positive follicular lymphoma (relapsed/refractory patients accepted for part 1a of the study - please call for details) | ||
| Target Population: | Persons 18 years+ with a diagnosis of stage II bulky or stage III/IV follicular lymphoma that is grade 1-3a | ||
| Type of Treatment: | IV Infusion | ||
| Link: | https://clinicaltrials.gov/study/NCT06097364 | ||
| NON HODGKINS LYMPHOMA - DLBCL | |||
| Regeneron (Olympia-3) | |||
| Status: | ACTIVE, RECRUITING | ||
| Title: | A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab, an anti -CD20 × anti-CD3 bispecific antibody, in combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3) | ||
| Purpose: | To determine the efficacy and safety, as well as tolerability and dose of Odronextamab (REGN1979) in combination with standard-of-care treatment (CHOP) compared to a standard of care regimen (R-CHOP) in patients with untreated diffuse large b-cell lymphoma | ||
| Target Population: | Persons 18+ with intermediate to high risk previously untreated CD20 positive DLBCL with measurable disease (relapsed/refractory patients accepted for part 1a of the study - please call for details) | ||
| Type of Treatment: | IV Infusion | ||
| Link: | https://clinicaltrials.gov/study/NCT06091865 | ||
| NON HODGKINS LYMPHOMA - DLBCL | |||
| MorphoSys (MOR208C310) | |||
| Status: | ACTIVE, NOT RECRUITING | ||
| Title: | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab + Lenalidomide in Addition to R-CHOP vs R-CHOP in Previously Untreated, High-Intermediate and High-Risk Patients with Newly-Diagnosed Large B-Cell Lymphoma (DLBCL) | ||
| Purpose: | To compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL | ||
| Target Population: | Persons 18 years+ with previously untreated CD20+ DLBCL | ||
| Type of Treatment: | IV Infusion | ||
| Link: https://clinicaltrials.gov/study/NCT04824092 | |||
| Blood Disorders | |||
| Immune Thrombocytopenia (ITP) | |||
| Novartis (VAYHIT1) | |||
| Status: | ACTIVE, RECRUITING | ||
| Title: | A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1) | ||
| Purpose: | To evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count of 30 G/L or higher in adult participants with primary ITP | ||
| Target Population: | Persons 18 years+ with primary ITP diagnosed within 3 months before initiating first-line ITP therapy (corticosteroids, IVIG), and with a platelet count below 30 G/L before starting therapy | ||
| Type of Treatment: | IV Infusion | ||
| Link: | https://clinicaltrials.gov/study/NCT05653349 | ||
| Immune Thrombocytopenia (ITP) | |||
| Novartis (VAYHIT2) | |||
| Status: | ACTIVE, RECRUITING | ||
| Title: | A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First Line Steroid Treatment (VAYHIT2) | ||
| Purpose: | To evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids. | ||
| Target Population: | Persons 18 years+ with a diagnosis of primary ITP, with insufficient response to, or relapse after a first-line corticosteroid therapy. | ||
| Type of Treatment: | IV Infusion + Oral Medication | ||
| Link: | https://clinicaltrials.gov/study/NCT05653219 | ||
| Chemotherapy-Induced Thrombocytopenia | |||
| Amgen (PROCLAIM) | |||
| Status: | ACTIVE, RECRUITING | ||
| Title: | A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim (N-Plate) for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemo | ||
| Purpose: | To evaluate the efficacy of romiplostim for the treatment of CIT in To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy | ||
| Target Population: | Patients with NSCLC, ovarian cancer, or breast cancer who are experiencing chemotherapy- induced thrombocytopenia | ||
| Type of Treatment: | Injection | ||
| Link: | https://clinicaltrials.gov/study/NCT03937154 | ||
| Polycythemia Vera (PV) | |||
| Protagonist (VERIFY) | |||
| Status: | ACTIVE, Not Recruiting | ||
| Title: | A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera | ||
| Purpose: | To evaluate the safety and efficacy of resfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and improving symptoms of PV. | ||
| Target Population: | Persons 18 years+ who meet criteria for a diagnosis of polycythemia vera, and have had at least 3 phlebotomies due to inadequate hematocrit control in 6 months before the start of study treatment, or at least 5 phlebotomies in 12 months before the start of study treatment. | ||
| Type of Treatment: | Subcutaneous Injection | ||
| Link: | https://clinicaltrials.gov/study/NCT05210790 | ||
| Blood and Biomarker Studies | |||
| Exact Sciences (Ascend-2) | |||
| Title: | Detecting Cancers Earlier Through Elective Plasma-Cancer SEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II | ||
| Collection Type: | Blood | ||
| Status: | ACTIVE, RECRUITING | ||
| Exact Sciences (2021-05) | |||
| Title: | Specimen Collection Study to Evaluate Biomarkers in Subjects with Cancer (Blood & Tissue) | ||
| Collection Type: | Blood and Tissue | ||
| Status: | |||
| ACTIVE, RECRUITING | |||
| PrecisionMed (PMI-6504) | |||
| Title: | Collection of Blood, Urine, and Tissue Samples from Patients with Solid Malignant Tumors | ||
| Collection Type | Blood, Urine, Tissue | ||
| Status: | ACTIVE, RECRUITING | ||
| Dx Biosamples (DxB 1016-01) | |||
| Title: | Master Protocol for the Procurement of Human Biospecimens for in Vitro Diagnostic Studies and | ||
| Collection Type: | Varies | ||
| Status: | ACTIVE, RECRUITING | ||
| MT Group (MTG-022) | |||
| Title: | Treatment Naïve Biomarker Trials | ||
| Collection Type: | Blood | ||
| Status: | ACTIVE, RECRUITING |
Call us at (801) 689-3909
